6MK Stock Chart & Stats
€116.08
€0.94(0.82%)
At close: 4:00 PM EDT
€116.08
€0.94(0.82%)
Day’s Range― - ―
52-Week Range€66.40 - €118.42
Previous CloseN/A
Volume294.00
Average Volume (3M)1.94K
Market Cap
€278.84B
Enterprise Value€340.75K
Total Cash (Recent Filing)€5.70B
Total Debt (Recent Filing)€49.12B
Price to Earnings (P/E)36.6
Beta0.52
Next Earnings
Oct 29, 2026EPS Estimate
1.92Next Dividend Ex-DateN/A
Dividend Yield2.54%
Share Statistics
EPS (TTM)3.56
Shares Outstanding2,469,824,500
10 Day Avg. Volume1,120
30 Day Avg. Volume1,940
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)5.01
Price to Sales (P/S)4.06
P/FCF Ratio21.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€118.80Price Target Upside2.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)2.42
Revenue Forecast (FY)€57.99B
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent, sizable free cash flow (~$14.1B TTM, +14%) provides durable internal funding for R&D, launches, dividends, buybacks and debt servicing. Strong cash generation creates a multi-quarter buffer to execute pipeline investments and absorb one-time charges without immediate capital raises.
Broad Pipeline And Recent Regulatory WinsRecent approvals (LIPFENDRA) and multiple positive Phase III readouts plus HIV and oncology program progress materially derisk the product slate and expand addressable markets. A deeper, diversified pipeline supports multi-year revenue growth beyond legacy products and reduces single-product concentration risk.
High Margins And Operating ProfitabilitySustained high gross and operating margins indicate structural pricing power, efficient manufacturing and premium product mix (specialty medicines, vaccines). Margin strength underpins reinvestment capacity and long-term cash conversion, supporting durable returns even with modest top-line growth.
Bears Say
Elevated LeverageMeaningful reliance on debt (D/E ~1.07 TTM) limits financial flexibility. Higher leverage increases sensitivity to profit swings and raises interest burden, constraining the company’s ability to ramp discretionary R&D or M&A without adding cost or reducing shareholder returns during prolonged downturns.
Acquisition Charges And Higher Financing CostsThe large upfront Terns charge and associated financing (guidance cites ~$0.12/sh ongoing MK‑4208/financing costs) create durable near-term margin and EPS headwinds, distort GAAP profitability and raise effective tax volatility, reducing reported earnings predictability for several quarters.
Earnings VolatilitySharp swings in profitability (near-breakeven in 2023 then rebound) reflect exposure to one-offs, inventory/reserve adjustments and product timing. Persistent volatility undermines forecasting, complicates capital allocation, and increases risk that leverage or investments may stress cash coverage under adverse scenarios.
Merck & Company News
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €66.40 and its highest was €118.42 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is €278.84B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Oct 29, 2026 which is in 84 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Aug 04, 2026. The company reported -€0.112 earnings per share for the quarter, beating the consensus estimate of -€0.234 by €0.121.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €0.737 which represents an annual dividend yield of 2.54%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 1.92.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,469,824,500 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of -€0.112 in its last earnings report, beating expectations of -€0.234. Following the earnings report the stock price went up 0.397%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in DE:6MK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€118.80 (2.34% Upside)
€118.80 (2.34% Upside)
Blogger Sentiment
Bullish
DE:6MK Sentiment 90%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 91%
Bearish news 9%
Bearish news 9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.04%
12-Months-Change
Fundamentals
Return on Equity
2.54%
Trailing 12-Months
Asset Growth
11.78%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
6MK Company Deck
6MK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and scientific story: core revenue growth (Q2 +5%), several strong product performances (KEYTRUDA, WELIREG, WINREVAIR), meaningful vaccine and pneumococcal momentum, multiple important regulatory approvals and positive Phase III readouts (LIPFENDRA approval, sac-TMT, tulisokibart induction, islatravir combos), and raised/narrowed revenue guidance. Offsetting these positives are material one-time charges from the Terns acquisition that produced a GAAP loss and drove a volatile tax rate, margin and expense pressure, one clinical setback (SSc-ILD), and some near-term commercial headwinds (OHTUVAYRE unwind, moderating KEYTRUDA U.S. growth). Overall, management emphasized pipeline derisking, continued launches, and long-term opportunity, while acknowledging short-term impacts from the acquisition and inventory/reserve dynamics.View all DE:6MK earnings summaries6MK Sales Breakdown
89.43% Pharmaceutical
9.77% Animal Health
0.79% Other
6MK Stock 12 Month Forecast
Average Price Target
€118.80
▲(2.34% Upside)